GoAI
Get started
BioAge Labs Inc. logo

BioAge Labs Inc.

BIOA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$9.48

−$0.21 · -2.17%

Aug 21, 4:00 PM ET

BIOA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

38

Expensive

Momentum

79

Gaining

Sentiment

60

Mixed

Risk resilience

60

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Kristen Fortney
Listed since
Sep 26, 2024
Employees
61

Market position

Day range

Current $9.48

52-week range

Current $9.48

Open
$9.81
Previous close
$9.69
Volume
453.45K
0.64× average
Average volume
712.3K
Average daily volume
Market cap
356.92M USD
Beta
0.93
Market reference 1
50-day average
$18.6311
-49.12% below average
200-day average
$16.8264
-43.66% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
292.06M USD
P/E (TTM)
-3.98×
P/B (TTM)
1.13×
P/S (TTM)
34.47×
EV / EBITDA
-3.66×
Earnings yield
-16.96%
Free cash flow yield
-17.32%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.39%
Operating margin
-1026.28%
Net margin
-912.25%
Return on equity
-29.63%
Return on assets
-27.33%
Return on invested capital
-33.38%

Financial health

Debt / equity
0.01×
Current ratio
14.24×

Financial statements

Income trends

Operating income

−92.78M USD-18.65%

Net income

−80.61M USD-13.35%
Income trends across reported periods−34.42M USD−55.64M USD−76.86M USD−98.09M USDOperating income, FY2022: −39.97M USDOperating income, FY2023: −48.4M USDOperating income, FY2024: −78.19M USDOperating income, FY2025: −92.78M USDNet income, FY2022: −39.72M USDNet income, FY2023: −63.85M USDNet income, FY2024: −71.11M USDNet income, FY2025: −80.61M USDFY2022FY2023FY2024FY2025
Operating income FY2022 −39.97M USD. Operating income FY2023 −48.4M USD. Operating income FY2024 −78.19M USD. Operating income FY2025 −92.78M USD. Net income FY2022 −39.72M USD. Net income FY2023 −63.85M USD. Net income FY2024 −71.11M USD. Net income FY2025 −80.61M USD.
Metric (USD)FY2025FY2024FY2023FY2022
Revenue9M USD———
Gross profit9M USD———
Research and development73.97M USD59.04M USD33.89M USD30.52M USD
Selling, general, and administrative27.81M USD19.16M USD14.51M USD9.45M USD
Operating expenses101.78M USD78.19M USD48.4M USD39.97M USD
Interest income13.09M USD9.63M USD2.43M USD465K USD
Interest expense697K USD2.37M USD7.79M USD241K USD
Depreciation and amortization213K USD167K USD162K USD129K USD
Operating income−92.78M USD−78.19M USD−48.4M USD−39.97M USD
Net income−80.61M USD−71.11M USD−63.85M USD−39.72M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
63%
5 beats, 3 misses, 0 met estimates
Average EPS surprise
-103.31%
8 comparable reports
Latest EPS result
-0.58
Estimate -0.61 · Beat by 4.50%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.31-0.56-0.8-1.05Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -1, estimate -0.58, surprise -72.42%, Miss. Q2 2025, reported May 6, 2025: actual -0.36, estimate -0.52, surprise +30.77%, Beat. Q3 2025, reported Aug 6, 2025: actual -0.6, estimate -0.56, surprise -7.14%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.56, estimate -0.67, surprise +16.42%, Beat. Q1 2026, reported Mar 24, 2026: actual -0.72, estimate -0.83, surprise +13.25%, Beat. Q2 2026, reported May 8, 2026: actual -0.52, estimate -0.64, surprise +18.70%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.58, estimate -0.607, surprise +4.50%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.608, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates3.28M2.34M1.41M473.17KQ1 '25EstimateQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual —, estimate 556.67K USD, surprise —, Comparison unavailable. Q2 2025, reported May 6, 2025: actual 1.45M USD, estimate 580K USD, surprise +150.17%, Beat. Q3 2025, reported Aug 6, 2025: actual 2.41M USD, estimate 870K USD, surprise +177.24%, Beat. Q4 2025, reported Nov 6, 2025: actual 2.05M USD, estimate 1.14M USD, surprise +80.18%, Beat. Q1 2026, reported Mar 24, 2026: actual 3.08M USD, estimate 1.4M USD, surprise +119.86%, Beat. Q2 2026, reported May 8, 2026: actual 2.77M USD, estimate 1.08M USD, surprise +155.88%, Beat. Q3 2026, reported Aug 6, 2026: actual 2.45M USD, estimate 1.5M USD, surprise +63.65%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.53M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

5 institutions
NeedhammaintainBuy
Morgan StanleyupgradeUnderweightEqual Weight

BIOA news

defenseworld.net

214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ: BIOA) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The…

Read source
zacks.com

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.6 per share a year ago.

Read source
globenewswire.com

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026

Read source
benzinga.com

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies.

Read source
defenseworld.net

BioAge Labs (NASDAQ:BIOA) Trading Up 5.5% – Should You Buy?

BioAge Labs, Inc. (NASDAQ: BIOA - Get Free Report)'s stock price rose 5.5% on Friday. The stock traded as high as $23.09 and last traded at $23.3710. Approximately 51,852 shares changed hands during mid-day trading, a…

Read source
globenewswire.com

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors Primary…

Read source

BIOA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BIOA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
10.31M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
8.74M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.33M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard U.S. Momentum Factor ETF logoVanguard U.S. Momentum Factor ETFVFMO
Market value
3.13M
Weight
0.16%
AUM
1.8B USD
Expense ratio
0.13%
Price / 1D
$232.52+0.68%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
3.1M
Weight
0.55%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.86M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
2.28M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
1.89M
Weight
0.03%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%

Continue in GoAI

Research BIOA

research.disclaimer